^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MYD88 mutation

i
Other names: MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D
Entrez ID:
Related biomarkers:
Phase N/A
BeiGene
Recruiting
Last update posted :
04/30/2024
Initiation :
03/03/2023
Primary completion :
12/01/2026
Completion :
12/01/2027
MYD88
|
MYD88 mutation • MYD88 L265P • MYD88 wild-type
|
Brukinsa (zanubrutinib)
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
07/09/2020
Primary completion :
06/06/2022
Completion :
02/01/2028
BCL2 • MYD88
|
MYD88 mutation
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)
Phase 2
Fudan University
Recruiting
Last update posted :
03/22/2022
Initiation :
01/04/2022
Primary completion :
01/04/2024
Completion :
01/04/2026
TP53 • MYC • MYD88 • CD79B
|
TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Phase N/A
Central Hospital, Nancy, France
Completed
Last update posted :
08/06/2021
Initiation :
02/01/2016
Primary completion :
06/01/2020
Completion :
07/01/2020
MYD88
|
MYD88 mutation • MYD88 L265P
Phase N/A
University Hospital, Bordeaux
Unknown status
Last update posted :
04/29/2020
Initiation :
02/19/2019
Primary completion :
05/01/2020
Completion :
05/01/2020
BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
|
CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation